535 related articles for article (PubMed ID: 34560890)
1. Graves' disease coexisted with resistance to thyroid hormone: a case report.
Akahori H; Usuda R
J Med Case Rep; 2021 Sep; 15(1):473. PubMed ID: 34560890
[TBL] [Abstract][Full Text] [Related]
2. Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report.
Arai N; Inaba M; Ichijyo T; Kagami H; Mine Y
J Med Case Rep; 2017 Jan; 11(1):9. PubMed ID: 28061802
[TBL] [Abstract][Full Text] [Related]
3. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of Resistance to Thyroid Hormone due to a Rare Mutation in the Thyroid Hormone Receptor Beta Gene in a Patient Previously Presumed to Have Graves' Disease.
Olatunbosun ST; Kluesner JK; Clerc PG; Prasad SS
Mil Med; 2024 Jan; 189(1-2):e439-e442. PubMed ID: 37531455
[TBL] [Abstract][Full Text] [Related]
5. Thyroid storm with encephalopathic symptoms due to Graves' disease and inappropriate secretion of thyrotropin.
Modignani RL; Venegoni M; Beretta F; Fassina S
Ann Ital Med Int; 1992; 7(4):250-4. PubMed ID: 1298337
[TBL] [Abstract][Full Text] [Related]
6. Resistance to thyroid hormone in a patient with coexisting Graves' disease.
Sivakumar T; Chaidarun S
Thyroid; 2010 Feb; 20(2):213-6. PubMed ID: 20151830
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of primary hyperthyroidism caused by Graves' disease admixed with resistance to thyroid hormone (P453T).
Sato H
Endocr J; 2010; 57(8):687-92. PubMed ID: 20574139
[TBL] [Abstract][Full Text] [Related]
8. Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery.
Slyper AH; Wyatt D; Boudreau C
J Pediatr Endocrinol Metab; 2005 Jun; 18(6):597-602. PubMed ID: 16042328
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease in a mediastinal mass presenting after total thyroidectomy for nontoxic multinodular goiter: a case report.
Cunha FM; Rodrigues E; Oliveira J; Saavedra A; Vinhas LS; Carvalho D
J Med Case Rep; 2016 Mar; 10():70. PubMed ID: 27029843
[TBL] [Abstract][Full Text] [Related]
10. Fetal Goitrous Hyperthyroidism in a Pregnant Woman with Triiodothyronine-Predominant Graves' Disease.
Washio K; Uenaka M; Tanimura K; Deguchi M; Nishida K; Fujioka K; Yamada H
Kobe J Med Sci; 2021 Feb; 66(4):E153-E158. PubMed ID: 33994519
[TBL] [Abstract][Full Text] [Related]
11. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
12. Graves' disease: diagnostic and therapeutic challenges (multimedia activity).
Kahaly GJ; Grebe SK; Lupo MA; McDonald N; Sipos JA
Am J Med; 2011 Jun; 124(6):S2-3. PubMed ID: 21605717
[TBL] [Abstract][Full Text] [Related]
13. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
14. Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.
Kubo T; Toki J; Kado Y; Kurihara M; Moriwake T; Kanzaki S; Seino Y
Endocr J; 2000 Apr; 47(2):197-201. PubMed ID: 10943745
[TBL] [Abstract][Full Text] [Related]
15. Thyroid-Stimulating Antibody/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves' Orbitopathy.
Nakano M; Konishi H; Koshiba M
Endocr Pract; 2022 Oct; 28(10):1050-1054. PubMed ID: 35870804
[TBL] [Abstract][Full Text] [Related]
16. Extremely high doses of radioiodine required for treatment of Graves' hyperthyroidism: a case report.
Neto AM; Tambascia MA; Brunetto S; Ramos CD; Zantut-Wittmann DE
Cases J; 2009 Aug; 2():8479. PubMed ID: 19918435
[TBL] [Abstract][Full Text] [Related]
17. Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease.
Higuchi R; Kumagai T; Kobayashi M; Minami T; Koyama H; Ishii Y
Pediatrics; 2001 Apr; 107(4):E57. PubMed ID: 11335778
[TBL] [Abstract][Full Text] [Related]
18. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
19. New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report.
Yamada H; Okajima F; Onda T; Fujimori S; Emoto N; Sugihara H
BMC Endocr Disord; 2020 Aug; 20(1):132. PubMed ID: 32847555
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves' hyperthyroidism.
Kamoun M; d'Herbomez M; Lemaire C; Fayard A; Desailloud R; Huglo D; Wemeau JL
Eur Thyroid J; 2014 Mar; 3(1):60-4. PubMed ID: 24847468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
